PCSK9 and lipid lowering drugs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PCSK9 and lipid lowering drugs

Published:2014-11 Issue: Volume:437 Page:66-71
ISSN:0009-8981
Container-title:Clinica Chimica Acta
language:en
Short-container-title:Clinica Chimica Acta

Author:

Guo Yuan-Lin,Zhang Wei,Li Jian-Jun^ORCID

Funder

National Natural Science Foundation of China

Specialized Research Fund for the Doctoral Program of Higher Education of China

Capital Special Foundation for Clinical Application Research

Fu Wai Hospital Youth Fund

Publisher

Elsevier BV

Subject

Biochemistry, medical,Clinical Biochemistry,Biochemistry,General Medicine

Reference75 articles.

1. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation;Seidah;Proc Natl Acad Sci U S A,2003

2. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia;Abifadel;Nat Genet,2003

3. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32;Varret;Am J Hum Genet,1999

4. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease;Cohen;N Engl J Med,2006

5. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 D374Y exhibit lower plasma concentrations of PCSK9;Humphries;Clin Chem,2009

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolomics combined with network pharmacology reveals the protective effect of astragaloside IV on alcoholic liver disease;Phytomedicine;2024-12

2. The benefits of PCSK9 inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis;Emergency and Critical Care Medicine;2024-02-29

3. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia;International Journal of Molecular Sciences;2023-02-16

4. Target-Based Screening for Lead Discovery;Interdisciplinary Biotechnological Advances;2023

5. Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic–Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density Lipoprotein Cholesterol in a Pooled Analysis of Randomized Phase I/II/III Studies;European Journal of Drug Metabolism and Pharmacokinetics;2022-08-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3